GGrantIndex
← Leaderboards

Yuan Chen

University Of California, San Diego

$18,343,172
Attributed
$20,019,600
Total exposure
12
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,019,600 · 12

By mechanism

R01$18,780,680 · 8
T32$875,678 · 1
R21$207,500 · 1
R29$130,742 · 1
R03$25,000 · 1

Top collaborators

Most similar at University Of California, San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Ubiquitin

Research focus

UbiquitinMalignant NeoplasmsModificationProteinsPost-Translational Protein ProcessingLeadMolecularPathway InteractionsEnzymesInhibitor/AntagonistCellsBaseBiochemicalMediatingCancer TherapyResistanceResponseTherapeutic TargetPharmaceutical PreparationsMutationInnovationStructureDesignInsight

Grant awards (57)

SUMO Modification and Cancer Therapy$512,593
R01 · FY2025 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$336,735
T32 · FY2025 · CA
SUMO Modification and Cancer Therapy$486,964
R01 · FY2024 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$368,648
T32 · FY2024 · CA
SUMO Modification and Cancer Therapy$512,593
R01 · FY2023 · CA · contact PI
Surgical Oncologists as Scientists (SOAS) Training Program$170,295
T32 · FY2023 · CA
SUMO Modification and Cancer Therapy$502,341
R01 · FY2022 · CA · contact PI
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma$536,425
R01 · FY2021 · CA · contact PI
SUMO Modification and Cancer Therapy$512,188
R01 · FY2021 · CA · contact PI
K-Ras sumoylation in cell proliferation and transformation$484,800
R01 · FY2021 · CA
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma$549,284
R01 · FY2020 · CA · contact PI
K-Ras sumoylation in cell proliferation and transformation$497,482
R01 · FY2020 · CA
SUMO Modification and Cancer Therapy$412,437
R01 · FY2020 · GM · contact PI
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma$563,523
R01 · FY2019 · CA · contact PI
K-Ras sumoylation in cell proliferation and transformation$482,557
R01 · FY2019 · CA
SUMO Modification and Cancer Therapy$431,175
R01 · FY2019 · GM · contact PI
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma$580,951
R01 · FY2018 · CA · contact PI
K-Ras sumoylation in cell proliferation and transformation$497,482
R01 · FY2018 · CA
SUMO Modification and Cancer Therapy$431,175
R01 · FY2018 · GM · contact PI
Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma$580,951
R01 · FY2017 · CA · contact PI
K-Ras sumoylation in cell proliferation and transformation$514,857
R01 · FY2017 · CA
SUMO Modification and Cancer Therapy$445,267
R01 · FY2017 · GM · contact PI
SUMO modification and cancer therapy$425,680
R01 · FY2016 · GM · contact PI
SUMO modification and cancer therapy$511,259
R01 · FY2015 · GM · contact PI
SENP:Conformational Dynamics and Inhibition by Small Molecules$384,312
R01 · FY2015 · GM · contact PI
SENP:Conformational Dynamics and Inhibition by Small Molecules$491,778
R01 · FY2014 · GM · contact PI
SUMO modification and cancer therapy$324,634
R01 · FY2014 · GM · contact PI
SUMO modification and cancer therapy$85,579
R01 · FY2014 · GM · contact PI
SENP:Conformational Dynamics and Inhibition by Small Molecules$53,733
R01 · FY2014 · GM · contact PI
SUMO modification and cancer therapy$417,900
R01 · FY2013 · GM · contact PI
SENP:Conformational Dynamics and Inhibition by Small Molecules$370,860
R01 · FY2013 · GM · contact PI
SENP:Conformational Dynamics and Inhibition by Small Molecules$384,310
R01 · FY2012 · GM · contact PI
High Throughput Assays to Identify Inhibitors of SUMO-mediated Protein-Protein In$41,500
R21 · FY2012 · NS · contact PI
SUMO modification and DNA damage response in cancer therapy$410,770
R01 · FY2011 · GM · contact PI
SUMO modification and DNA damage response in cancer therapy$397,705
R01 · FY2010 · GM · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$313,706
R01 · FY2010 · GM · contact PI
SUMO modification and DNA damage response in cancer therapy$54,787
R01 · FY2010 · GM · contact PI
SUMO modification and DNA damage response in cancer therapy$413,028
R01 · FY2009 · GM · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$366,931
R01 · FY2009 · GM · contact PI
High Throughput Assays to Identify Inhibitors of SUMO-mediated Protein-Protein In$166,000
R21 · FY2009 · NS · contact PI
SUMO modification and DNA damage response in cancer therapy$69,722
R01 · FY2009 · GM · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$55,387
R01 · FY2009 · GM · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$385,507
R01 · FY2008 · GM · contact PI
SUMO modification and DNA damage response in cancer therapy$333,000
R01 · FY2008 · GM · contact PI
SUMO modification and DNA damage response in cancer therapy$63,191
R01 · FY2008 · GM · contact PI
A high throughput screening assay for the identification of SUMOylation inhibitor$25,000
R03 · FY2008 · DA · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$316,875
R01 · FY2007 · GM · contact PI
The Enzymatic Pathway of a Ubiquitin-Like Modification$40,190
R01 · FY2007 · GM · contact PI
NMR Studies of Ku70 and Ku80 Domains$361,727
R01 · FY2005 · CA
NMR Studies of Ku70 and Ku80 Domains$351,252
R01 · FY2004 · CA
NMR Studies of Ku70 and Ku80 Domains$341,084
R01 · FY2003 · CA
NMR Studies of Ku70 and Ku80 Domains$331,211
R01 · FY2002 · CA
NMR STUDIES OF PROTEIN INTERACTIONS IN UBIQUITINATION$287,332
R01 · FY2002 · GM
NMR Studies of Ku70 and Ku80 Domains$352,078
R01 · FY2001 · CA
NMR STUDIES OF PROTEIN INTERACTIONS IN UBIQUITINATION$279,067
R01 · FY2001 · GM
NMR STUDIES OF PROTEIN INTERACTIONS IN UBIQUITINATION$271,040
R01 · FY2000 · GM
NMR STUDY OF A NEW CLASS OF DNA BINDING DOMAINS$130,742
R29 · FY2000 · GM